ATE170839T1 - Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten - Google Patents

Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten

Info

Publication number
ATE170839T1
ATE170839T1 AT95910164T AT95910164T ATE170839T1 AT E170839 T1 ATE170839 T1 AT E170839T1 AT 95910164 T AT95910164 T AT 95910164T AT 95910164 T AT95910164 T AT 95910164T AT E170839 T1 ATE170839 T1 AT E170839T1
Authority
AT
Austria
Prior art keywords
indole derivatives
estrogen
treatment
neoplasms
diseases
Prior art date
Application number
AT95910164T
Other languages
English (en)
Inventor
Alan J Bitonti
Ian A Mcdonald
Francesco G Salituro
Jeffrey P Whitten
Esa T Jarvi
Paul S Wright
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of ATE170839T1 publication Critical patent/ATE170839T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT95910164T 1994-02-22 1995-01-31 Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten ATE170839T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20005794A 1994-02-22 1994-02-22
US36204694A 1994-12-22 1994-12-22

Publications (1)

Publication Number Publication Date
ATE170839T1 true ATE170839T1 (de) 1998-09-15

Family

ID=26895427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95910164T ATE170839T1 (de) 1994-02-22 1995-01-31 Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten

Country Status (17)

Country Link
US (1) US5877202A (de)
EP (1) EP0746544B1 (de)
JP (1) JP3536258B2 (de)
KR (1) KR100362864B1 (de)
CN (1) CN1141627A (de)
AT (1) ATE170839T1 (de)
AU (1) AU680740B2 (de)
CA (1) CA2183731C (de)
DE (1) DE69504637T2 (de)
DK (1) DK0746544T3 (de)
ES (1) ES2122555T3 (de)
FI (1) FI963272A0 (de)
HU (1) HUT76133A (de)
IL (1) IL112700A0 (de)
NO (1) NO963483L (de)
NZ (1) NZ281431A (de)
WO (1) WO1995022524A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6200760B1 (en) * 1997-02-24 2001-03-13 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
WO1999059969A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
MXPA02002654A (es) * 1999-09-13 2002-07-30 Wyeth Corp Glucopiranosidos conjugados de 2-(4-hidroxi -fenil)-1- [4-(2-amin- 1-il-etoxi) -bencil] -1h -indol -5- oles.
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6326501B1 (en) * 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
CA2424222A1 (en) * 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
FR2842526B1 (fr) 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
JP2006524239A (ja) * 2003-03-27 2006-10-26 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼用組成物
US7491744B2 (en) 2004-04-26 2009-02-17 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
US8765488B2 (en) 2004-07-22 2014-07-01 The Board Of Trustees Of The University Of Illinois Sensors employing single-walled carbon nanotubes
CA2631082C (en) 2005-11-23 2015-02-03 Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
JP5758395B2 (ja) 2009-10-15 2015-08-05 ザ チルドレンズ メディカル センター コーポレイション 疼痛を治療するためのセピアプテリンレダクターゼ阻害薬
EP2611764A4 (de) 2010-08-30 2016-12-14 Arzeda Corp Fermentierungsroute zur herstellung von levulinsäure, levulinatestern, valerolacton und deren derivaten
US9346803B2 (en) 2011-10-17 2016-05-24 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
ES2802251T3 (es) * 2012-01-06 2021-01-18 Novartis Ag Compuestos heterocíclicos y métodos para su uso
US9182350B2 (en) * 2012-03-05 2015-11-10 Dalian University Of Technology Naphthalene-based two-photon fluorescent probes, preparation method and use thereof
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
JP7161475B2 (ja) * 2016-12-28 2022-10-26 プロメガ コーポレイション 官能化ｎａｎｏｌｕｃ阻害剤
EP4334285A4 (de) * 2021-05-05 2025-07-30 Kare Chemical Tech Inc Katalytische tryptamin-verfahren und vorläufer
CN116410120A (zh) * 2023-04-19 2023-07-11 四川农业大学 一种2-苯基吲哚酰胺类抗肿瘤化合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1482845A (fr) * 1964-12-31 1967-06-02 Merck & Co Inc Composés de l'indol
DK0431520T3 (da) * 1989-12-04 1995-04-10 Searle & Co Heterocycliske acylaminodiol-beta-aminosyrederivater
JPH05504968A (ja) * 1990-03-07 1993-07-29 ローン―プーラン・ロレ・ソシエテ・アノニム グリシンアミド誘導体、その製造及びそれを含む医薬品
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
WO1993023374A1 (fr) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
JPH0835029A (ja) * 1994-07-19 1996-02-06 Toyota Motor Corp 高強度高延性鋳造アルミニウム合金およびその製造方法

Also Published As

Publication number Publication date
CN1141627A (zh) 1997-01-29
US5877202A (en) 1999-03-02
HUT76133A (en) 1997-06-30
DE69504637D1 (de) 1998-10-15
NZ281431A (en) 1997-09-22
AU1837395A (en) 1995-09-04
JP3536258B2 (ja) 2004-06-07
IL112700A0 (en) 1995-05-26
NO963483D0 (no) 1996-08-21
FI963272A7 (fi) 1996-08-21
DE69504637T2 (de) 1999-05-06
FI963272L (fi) 1996-08-21
NO963483L (no) 1996-10-22
WO1995022524A1 (en) 1995-08-24
ES2122555T3 (es) 1998-12-16
DK0746544T3 (da) 1999-06-07
EP0746544A1 (de) 1996-12-11
JPH09509169A (ja) 1997-09-16
CA2183731C (en) 2000-03-21
AU680740B2 (en) 1997-08-07
KR100362864B1 (ko) 2003-04-16
FI963272A0 (fi) 1996-08-21
HU9602299D0 (en) 1996-10-28
CA2183731A1 (en) 1995-08-24
EP0746544B1 (de) 1998-09-09

Similar Documents

Publication Publication Date Title
DE69504637D1 (de) Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE282413T1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69831406D1 (de) Verwendung von thiazolidinedion-derivaten zur behandlung des polyzystischen ovarien syndroms und des schwangerschaftsdiabetes
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
ATE221781T1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DE69413829D1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE190839T1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
DE60005952T8 (de) Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten
ATE264101T1 (de) Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE60006519D1 (de) Glutathion-reduktase zur behandlung und prophylaxe von aids
NO980375L (no) Humant MP52 Arg protein
ATE279214T1 (de) Auf bibapcitide gegründete pharmaceutische zusammensetzungen für bildgebung und behandlung von thromben
RU94000387A (ru) Способ лечения врожденного вывиха надколенника

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee